You are currently viewing a new version of our website. To view the old version click .
Proceedings
  • Extended Abstract
  • Open Access

10 September 2019

(2-Imidazolin-4-yl)phosphonates: Green Chemistry and Biology Walk Together †

,
,
,
,
,
,
,
,
and
1
Laboratory of Medicinal Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine of the University of Barcelona (IBUB), 08028 Barcelona, Spain
2
Pharmacology Section, Department of Pharmacology, Toxicology and Therapeutic Chemistry,Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, 08028Barcelona, Spain
3
Unit of Pharmaceutical Technology, Pharmacy and Pharmaceutical Technology Department, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain
4
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, Serbia
This article belongs to the Proceedings The 2nd Molecules Medicinal Chemistry Symposium (MMCS): Facing Novel Challenges in Drug Discovery
2-Imidazoline-containing compounds constitute a valuable class of agents that modulate α2-adrenergic receptors and often show a high affinity for imidazoline I2-receptors (I2-IR). Moreover, 2-imidazolines are an important class of heterocyclic scaffolds found in natural product chemistry, coordination chemistry, and homogeneous catalysis. To meet the demand for 2-imidazoline-containing compounds, different synthetic approximations were developed. In this work, we describe an efficient and user-friendly synthetic process involving the combination of isocyanide-based multicomponent reaction and microwave heating without the need of anhydrous atmosphere or additional solvents that generates unprecedented (2-imidazolin-4-yl)phosphonates [1].
We assessed the pharmacological profile and selectivity of the prepared compounds upon I2-IR. Owing to the outstanding high I2-IR affinity of one of the prepared compounds and high selectivity devoid to the α2-adrenoceptor of other compounds, markedly better than any described I2-IR ligand to date, (2-imidazolin-4-yl)phosphonates might be considered as a suitable scaffold for designing novel I2-IR ligands [2]. In addition, we demonstrated the effectiveness of two of the new I2-IR ligands in an in vivo female model for cognitive decline (SAMP8), and we analyzed the pathological biomarkers for neurodegeneration. This study is the first experimental evidence that demonstrates the possibility of using this receptor as a target for cognitive impairment [3].
Note, theoretical studies were carried out for designing compounds with enhanced activity and selectivity upon I2-IR based on created 3D-QSAR model.
In this work, green chemistry to access an unprecedented scaffold and promising pharmacological results in the neurodegeneration field walked together.

Acknowledgments

Financial support Projects SAF2016-77703-C2-1-R and 2017SGR106 is grateful acknowledged. A.B. thanks the Institute of Biomedicine of the Universitat de Barcelona (IBUB) and S.R.-A. thanks the Ministerio de Economia, Industria y Competitividad (FPI program) for their PhD grants.

References

  1. Abas, S.; Estarellas, C.; Luque, F.J.; Escolano, C. Easy access to (2-imidazolin-4-yl) phosphonates by a microwave assisted multicomponent reaction. Tetrahedron 2015, 71, 2581–2872. [Google Scholar] [CrossRef]
  2. Abás, S.; Erdozain, A.M.; Keller, B.; Rodríguez-Arévalo, S.; Callado, L.F.; García-Sevilla, J.A.; Escolano, C. Neuroprotective Effects of a Structurally New Family of High Affinity Imidazoline I2 Receptor Ligands. ACS Chem. Neurosci. 2017, 8, 737–742. [Google Scholar] [CrossRef] [PubMed]
  3. Griñán-Ferré, C.; Vasilopoulou, F.; Abás, S.; Rodríguez-Arévalo, S.; Bagán, A.; Sureda, F.X.; Pérez, B.; Callado, L.F.; García-Sevilla, J.A.; García-Fuster, M.J.; et al. Behavioral and Cognitive Improvement Induced by Novel Imidazoline I2 Receptor Ligands in Female SAMP8 Mice. Neurotherapeutics 2018, 16, 416–431. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.